Abstracts tagged "Psoriatic arthritis"

Abstract Number: 165 • 2015 ACR/ARHP Annual Meeting
Validation of a New Ultrasound Criteria for Subclinical Synovitis in Chronic Inflammatory Polyarthritis
Julio Ramírez¹, Jose Inciarte-Mundo², Andrea Cuervo¹, Virginia Ruiz-Esquide², M. Victoria Hernández³, Raimon Sanmarti² and Juan D. Cañete², ¹Arthritis Unit. Rheumatology, Hospital Clínic of Barcelona, Barcelona, Spain, ²Rheumatology Department, Hospital Clinic i Provincial, Barcelona, Spain, ³Arthritis Unit, Rheumatology, Hospital Clinic, Barcelona, Spain
Background/Purpose: We have previously reported that patients with subclinical synovitis defined by synovial hypertrophy grade >2 (SH>2) plus power Doppler (PD) signal had higher disease…
Abstract Number: 2839 • 2015 ACR/ARHP Annual Meeting
Disease Activity and Safety during Long-Term (104-Week) Treatment with Apremilast, an Oral Phosphodiesterase 4 Inhibitor, in Patients with Psoriatic Arthritis: Results from a Phase III, Randomized, Controlled Trial and Open-Label Extension
Christopher J. Edwards¹, Francisco J. Blanco², Jeffrey Crowley³, ChiaChi Hu⁴, Kamal Shah⁴ and Charles A. Birbara⁵, ¹University Hospital Southampton, Southampton, United Kingdom, ²Osteoarticular and Aging Research Lab. Proteomics Unit - Associated Node to ProteoRed, Rheumatology Division, Proteomics Group-ProteoRed/ISCIII, INIBIC-CHUAC, A Coruña, Spain, ³Bakersfield Dermatology, Bakersfield, CA, ⁴Celgene Corporation, Warren, NJ, ⁵University of Massachusetts Medical School, Worcester, MA
Background/Purpose: Apremilast (APR), an oral phosphodiesterase 4 inhibitor, acts to regulate immune responses in psoriatic arthritis (PsA). PALACE 3 compared the efficacy and safety of…
Abstract Number: 591 • 2015 ACR/ARHP Annual Meeting
Rosuvastatin Improves Endothelial Function in Patients with Inflammatory Joint Diseases, Longitudinal Associations with Atherosclerosis and Arteriosclerosis
Eirik Ikdahl¹, Jonny Hisdal², Silvia Rollefstad¹, Inge C Olsen³, Tore K. Kvien⁴, Terje R. Pedersen⁵ and Anne Grete Semb⁶, ¹Preventive Cardio-Rheuma Clinic, Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ²Section of Vascular Investigations, Oslo University Hospital Aker, Oslo, Norway, ³Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁴Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁵Department of Preventive Cardiology, Ullevaal University Hospital, Oslo, Norway, ⁶Preventive Cardio-Rheuma clinic, Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway
Background/Purpose: Endothelial dysfunction is an early step in the formation of atherosclerotic lesions and can be quantified by the degree of flow mediated vasodilation (FMD)…
Abstract Number: 2843 • 2015 ACR/ARHP Annual Meeting
Long-Term (156-Week) Efficacy and Safety Profile of Apremilast, an Oral Phosphodiesterase 4 Inhibitor, in Patients with Psoriatic Arthritis: Results from a Phase III, Randomized, Controlled Trial and Open-Label Extension (PALACE 1)
Arthur Kavanaugh¹, Adewale O. Adebajo², Dafna D. Gladman³, Juan J. Gomez-Reino⁴, Stephen Hall⁵, Eric Lespessailles⁶, Philip J. Mease⁷, Georg A. Schett⁸, Kamal Shah⁹, Lichen Teng⁹ and Jürgen Wollenhaupt¹⁰, ¹University of California, San Diego School of Medicine, LaJolla, CA, ²University of Sheffield, Sheffield, United Kingdom, ³Department of Medicine, Division of Rheumatology, University of Toronto, Toronto, ON, Canada, ⁴Hospital Clinico Universitario, Santiago, Spain, ⁵Monash University, Melbourne, Australia, ⁶University of Orléans, Orléans, France, ⁷Rheumatology Research, Swedish Medical Center, Seattle, WA, ⁸University of Erlangen-Nuremberg, Erlangen, Germany, ⁹Celgene Corporation, Warren, NJ, ¹⁰Schön Klinik Hamburg Eilbek, Hamburg, Germany
Background/Purpose: Apremilast (APR), an oral phosphodiesterase 4 inhibitor, has demonstrated clear efficacy and good tolerability in psoriatic arthritis (PsA) and psoriasis. Longer term data are…
Abstract Number: 604 • 2015 ACR/ARHP Annual Meeting
Calprotectin and TNF Antagonist Serum Trough Levels Identify Active Ultrasound Synovitis in Rheumatoid Arhritis and Psoriatic Arthritis Patients in Remission or Low Disease Activity
Jose Inciarte-Mundo¹, Julio Ramírez¹, Virginia Ruiz-Esquide¹, M. Victoria Hernández¹, Oscar Camacho¹, Sonia Cabrera-Villalba¹, Andrea Cuervo¹, Mariona Pascal², Jordi Yagüe², Juan D. Cañete¹ and Raimon Sanmarti¹, ¹Rheumatology Department, Hospital Clinic i Provincial, Barcelona, Spain, ²Immunology Department, Hospital Clinic i Provincial, Barcelona, Spain
Background/Purpose: An accurate assessment of disease activity is needed in Rheumatoid arthritis (RA) and Psoriatic Arthritis (PsA) patients in remission or low disease activity for…
Abstract Number: 2849 • 2015 ACR/ARHP Annual Meeting
Apremilast, an Oral Phosphodiesterase 4 Inhibitor, Is Associated with Long-Term (104-Week) Improvement in Fatigue in Patients with Psoriatic Arthritis: Pooled Results from 3 Phase 3, Randomized, Controlled Trials
Arthur Kavanaugh¹, Dafna Gladman², Christopher J. Edwards³, Airi Poder⁴, Frederic Liote⁵, Paul A. Bird⁶, Georg Schett⁷, Melissa McIlraith⁸, Lichen Teng⁸ and Philip J. Mease⁹, ¹University of California, San Diego School of Medicine, LaJolla, CA, ²Toronto Western Research Institute, Toronto, ON, Canada, ³University Hospital Southampton, Southampton, United Kingdom, ⁴Clinical Research Centre Ltd, Tartu, Estonia, ⁵University Paris Diderot, Paris, France, ⁶University of New South Wales, Sydney, Australia, ⁷Department of Internal Medicine 3 and Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, ⁸Celgene Corporation, Warren, NJ, ⁹Swedish Medical Center and University of Washington School of Medicine, Seattle, WA
Background/Purpose: Patients (pts) with active psoriatic arthritis (PsA) have disease involvement across multiple domains. Pts can have substantial fatigue, which is increasingly being recognized as…
Abstract Number: 665 • 2015 ACR/ARHP Annual Meeting
Construct Validity of Disease Activity for Psoriatic Arthritis Composite Index and Tentative Cut-Off Values in a Cohort of Patients with Psoriatic Arthritis
Josefina Gallino Yanzi¹, Emilce Schneeberger¹, Osvaldo Luis Cerda¹, Cecilia Zaffarana¹, Margarita Landi¹, Marcos G. Rosemffet², Natalia Zamora³, Tomas Cazenave², Fernando Dal Pra¹, Paula Kohan⁴, Emilio Buschiazzo⁵ and Gustavo Citera², ¹Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, ²Rheumatology, Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, ³Reumatologia, Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, ⁴Hospital Dr. E. Tornu, Buenos Aires, Argentina, ⁵Rheumatology, Hospital Sr Del Milagro, Salta, Argentina
Background/Purpose: Disease Activity for Psoriatic Arthritis (DAPSA) is a composite index that assesses disease activity in patients with Psoriatic Arthritis (PsA) taking into account peripheral…
Abstract Number: 2864 • 2015 ACR/ARHP Annual Meeting
Long-Term Work Productivity Improvement Associated with Apremilast, an Oral Phosphodiesterase 4 Inhibitor, in Patients with Psoriatic Arthritis: Pooled Analysis of 3 Phase 3 Studies
Frank Zhang¹, Zoe Clancy² and Stan Li³, ¹Pricing and Market Access, I&I, Celgene Corporation, Warren, NJ, ²33 Technology Drive, Celgene Corporation, Warren, NJ, ³Celgene Corporation, Warren, NJ
Background/Purpose: Studies have shown that patients with psoriatic arthritis (PsA) have significantly compromised physical health and quality of life, and negative effect on work productivity…
Abstract Number: 667 • 2015 ACR/ARHP Annual Meeting
Comparison of Patient and Provider Assessments of Response to Therapy for Psoriatic Arthritis
Tobee Gunter¹ and Jessica Walsh², ¹Rheumatology, School of Medicine, University of Utah Internal Medicine, Salt Lake City, UT, ²Division of Rheumatology, Salt Lake City Veteran Affairs and University of Utah Medical Centers, Salt Lake City, UT
Background/Purpose: Little is known about how psoriatic arthritis patients and their providers perceive response to therapy. Discrepancies in perceptions of therapy response may indicate that…
Abstract Number: 2873 • 2015 ACR/ARHP Annual Meeting
Pharmacological Treatment of Psoriatic Arthritis (PSA): Systematic Literature Review for the Update of the EULAR Recommendations for the Management of PSA
Sofia Ramiro¹, Josef S. Smolen², Robert B.M. Landewé³, Désirée van der Heijde¹, Maxime Dougados⁴, Paul Emery⁵, Maarten de Wit⁶, Maurizio Cutolo⁷, Susan Oliver⁸ and Laure Gossec⁹, ¹Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Department of Rheumatology, Medical University of Vienna, Vienna, Austria, ³Department of Rheumatology, Amsterdam Rheumatology Center, Amsterdam, Netherlands, ⁴Rheumatology Department, Cochin hospital, Paris-Descartes University, Paris, France, ⁵Section of Musculoskeletal Disease, Leeds Institute of Molecular Medicine, University of Leeds, Leeds, United Kingdom, ⁶EULAR Social Leagues, Zurich, Switzerland, ⁷Division of Clinical Immunology, Dept Internal Medicine, University of Genova, Genova, Italy, ⁸Independent Nurse Consultant, North Devon, United Kingdom, ⁹Rheumatology, Pitié Salpetriere Hospital, Paris, France
Background/Purpose: As part of the update of the EULAR recommendations for the management of PsA, we performed a systematic literature review to assess the efficacy…
Abstract Number: 670 • 2015 ACR/ARHP Annual Meeting
Evaluation of the Predictive Value of Non-Specific Musculoskeletal Symptoms in Preclinical Phases of Psoriatic Arthritis
Lihi Eder¹, Ari Polachek¹, Cheryl Rosen², Vinod Chandran¹, Richard J. Cook³ and Dafna D. Gladman¹, ¹Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²Dermatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ³Statistics and Actuarial Science, University of Waterloo, Waterloo, ON, Canada
Background/Purpose: Limited information exists about the characteristics of pre-clinical phases of psoriatic arthritis (PsA). We aimed to assess whether the presence and trends in non-specific…
Abstract Number: 2874 • 2015 ACR/ARHP Annual Meeting
Two-Years Survival of Golimumab in Patients with Rheumatoid Arthritis, Psoriatic Arthritis, and Axial Spondyloarthritis and Predictors Thereof in Real-Life Settings
Leonardo Santo¹, Angelo Semeraro², Carmelo Zuccaro³, Maria Grazia Anelli⁴, Romano Bucci⁵, Antonio Marsico⁶, Laura Quarta⁷, Giorgio Carlino⁸, Francesco Paolo Cantatore⁹, Annamaria Gaudio¹⁰, Fabio Cacciapaglia¹¹, Oriana Casilli¹², Paola Chiara Francesca Falappone¹³ and Florenzo Iannone¹⁴, ¹DSS4 Barletta, ASL BT Andria - Rheumatology Service, Barletta, Italy, ²Unità Operativa di Reumatologia ASL Taranto, Taranto, Italy, ³U.O.of Geriatrics, Outpatient clinic of Rheumatology, Brindisi, Italy, ⁴DIM, Rheumatology Unit, Bari, Italy, ⁵A.O.U., Rheumatology Hospital Unit, Foggia, Italy, ⁶Outpatient clinic of Rheumatology, Taranto,, Italy, ⁷Department of Rheumatology, "V.Fazzi" Hospital, San Cesario di Lecce, Italy, ⁸ASL LE - DSS Casarano and Gallipoli, Rheumatology Service, Gallipoli, Italy, ⁹Department of Rheumatology, University of Foggia,, Foggia, Italy, ¹⁰Department of Rheumatology, University of Foggia, Foggia, Italy, ¹¹Internal Medicine Unit and Outpatient clinic of Rheumatology, “N. Melli” Hospital, San Pietro Vernotico (BR), Italy, ¹²Department of Rheumatology, "Vito Fazzi" Hospital, San Cesario di Lecce, Italy, ¹³Internal Medicine Unit - Outpatient clinic of Rheumatology,, "S. Camillo de' Lellis" Hospital, Mesagne (BR), Italy, ¹⁴Interdisciplinary Department of Medicine (DIM), Rheumatology Unit, University of Bari, Bari, Italy
Background/Purpose: It has previously been shown that the survival of anti-TNF drugs was lower in Rheumatoid arthritis (RA) than in other chronic arthritis1. The objective…
Abstract Number: 675 • 2015 ACR/ARHP Annual Meeting
Vitamin D Deficiency in Rheumatoid Arthritis, Ankylosing Spondylitis and Psoriatic Arthritis. Results of the CARMA Study
Ana Urruticoechea¹, Maria Auxiliadora Martin², Santos Castañeda³, Carlos Alberto Sánchez-Piedra², Carlos González-Juanatey⁴, Javier Llorca⁵, Federico Díaz-González⁶ and Miguel Angel Gonzalez-Gay⁷, ¹Hospital Can Misses, Ibiza, Spain, ²Research Unit of Spanish Society of Rheumatology,, Madrid, Spain, ³Rheumatology, H.U. La Princesa, Madrid, Spain, ⁴Division or Cardiology, Hospital Lusus Augusti, Lugo, Spain, ⁵Department of Epidemiology and Computational Biology, School of Medicine, University of Cantabria, and CIBER Epidemiología y Salud Pública (CIBERESP), IDIVAL, Santander, Spain, ⁶Investigation Unit, Sociedad Española de Reumatológía, Madrid, Spain, ⁷Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Santander, Spain
Background/Purpose: To study the association between 25-hydroxyvitamin D (25(OH)D) levels and the clinical characteristics of patients with chronic inflammatory rheumatic diseases (CIRD). Methods: Cross section…
Abstract Number: 2888 • 2015 ACR/ARHP Annual Meeting
Apremilast, an Oral Phosphodiesterase 4 Inhibitor, Is Associated with Long-Term (104-Week) Improvements in Enthesitis and Dactylitis in Patients with Psoriatic Arthritis: Pooled Results from Three Phase III, Randomized, Controlled Trials
Dafna D. Gladman¹, Arthur Kavanaugh², Adewale O. Adebajo³, Juan J. Gomez-Reino⁴, Jürgen Wollenhaupt⁵, Maurizio Cutolo⁶, Georg A. Schett⁷, Eric Lespessailles⁸, Melissa McIlraith⁹, ChiaChi Hu⁹, Christopher J. Edwards¹⁰, Charles A. Birbara¹¹ and Philip J. Mease¹², ¹Toronto Western Hospital, Toronto, ON, Canada, ²University of California, San Diego School of Medicine, LaJolla, CA, ³University of Sheffield, Sheffield, United Kingdom, ⁴Hospital Clinico Universitario, Santiago, Spain, ⁵Schön Klinik Hamburg Eilbek, Hamburg, Germany, ⁶University of Genova, Genova, Italy, ⁷University of Erlangen-Nuremberg, Erlangen, Germany, ⁸University of Orléans, Orléans, France, ⁹Celgene Corporation, Warren, NJ, ¹⁰University Hospital Southampton, Southampton, United Kingdom, ¹¹University of Massachusetts Medical School, Worcester, MA, ¹²Rheumatology Research, Swedish Medical Center, Seattle, WA
Background/Purpose: Apremilast (APR), a PDE4 inhibitor, helps regulate immune responses in psoriatic arthritis (PsA). PALACE 1, 2, and 3 compared apremilast (APR) efficacy/safety with placebo…
Abstract Number: 1595 • 2014 ACR/ARHP Annual Meeting
Economic Evaluation of Sequencing Strategies in the Treatment of Psoriatic Arthritis in the United States
Thomas Tencer¹, Zoe Clancy¹, Helene Cawston², Sandrine Cure³ and Frank Zhang¹, ¹33 Technology Drive, Celgene Corporation, Warren, NJ, ²OptumInsight, Nanterre, France, ³OptumInsight, Uxbridge, United Kingdom
Background/Purpose: In the treatment of psoriatic arthritis (PsA), switching between alternative biologic treatments is common. A cost-effectiveness model was developed to assess the impact of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].